Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KDM6A | O15550 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 11/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20386661 | 0.81 | KDM4E (0.57) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL958138 | 0.80 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL8716751 | 0.80 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL13003558 | 0.78 | KDM4E (0.60) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL4394165 | 0.76 | KDM4E (0.58) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL5525055 | 0.75 | KDM4E (0.62) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL2511741 | 0.75 | KDM4E (0.57) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21523588 | 0.73 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL5136933 | 0.73 | APP (0.58) | KDM4ETP53CYP2D6HTTSMN1; SMN2 | |
| SCHEMBL13856905 | 0.73 | KDM4E (0.55) | KDM4ETP53CYP2D6HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298270-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009015203-A1 | NOVEL COMPOUNDS AND METHODS OF USING THEM | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298270-A1 | Novel Compounds and Methods of Using Them | HDAC1, HDAC3, HDAC6 | KDM4E 90/4885TP53 2351/4885CYP2D6 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.